Korro Bio, Inc. Foreign Currency Transaction Gain (Loss), before Tax
Korro Bio, Inc. (KRRO) reported Foreign Currency Transaction Gain (Loss), before Tax of -$5.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2023-03-10
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2022-12-31 was $2.00K.
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2022-09-30 was -$5.00K.
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2022-06-30 was -$3.00K.
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2022-03-31 was $1.00K, a 95.24% decline year-over-year.
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$5.00K, a 131.25% decline from fiscal 2021.
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for fiscal 2021 was $16.00K.
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for fiscal 2020 was -$4.00K, a 157.14% decline from fiscal 2019.
- Korro Bio, Inc. foreign currency transaction gain (loss), before tax for fiscal 2019 was $7.00K, a 95.36% decline from fiscal 2018.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$3.00K derived: sum of 2 quarters · filed 2023-03-10 | -$6.00K derived: sum of 3 quarters · filed 2023-03-10 | -$5.00K 10-K · filed 2023-03-10 |
| 2022-09-30 | -$5.00K 10-Q · filed 2022-11-08 | -$8.00K derived: sum of 2 quarters · filed 2022-11-08 | -$7.00K 10-Q · filed 2022-11-08 | -$7.00K derived: sum of 4 quarters · filed 2023-03-10 |
| 2022-06-30 | -$3.00K 10-Q · filed 2022-08-09 | -$2.00K 10-Q · filed 2022-08-09 | -$2.00K derived: sum of 3 quarters · filed 2023-03-10 | -$6.00K derived: sum of 4 quarters · filed 2023-03-10 |
| 2022-03-31 | $1.00K 10-Q · filed 2022-05-04 | $1.00K derived: sum of 2 quarters · filed 2023-03-10 | -$3.00K derived: sum of 3 quarters · filed 2023-03-10 | -$4.00K derived: sum of 4 quarters · filed 2023-03-10 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$4.00K derived: sum of 2 quarters · filed 2023-03-10 | -$5.00K derived: sum of 3 quarters · filed 2023-03-10 | $16.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | -$4.00K 10-Q · filed 2022-11-08 | -$5.00K derived: sum of 2 quarters · filed 2022-11-08 | $16.00K 10-Q · filed 2022-11-08 | -$15.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$1.00K 10-Q · filed 2022-08-09 | $20.00K 10-Q · filed 2022-08-09 | -$11.00K derived: sum of 3 quarters · filed 2022-08-09 | $7.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $21.00K 10-Q · filed 2022-05-04 | -$10.00K derived: sum of 2 quarters · filed 2022-05-04 | $8.00K derived: sum of 3 quarters · filed 2022-05-04 | $16.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$13.00K derived: sum of 2 quarters · filed 2022-03-15 | -$5.00K derived: sum of 3 quarters · filed 2022-03-15 | -$4.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $18.00K 10-Q · filed 2021-11-15 | $26.00K derived: sum of 2 quarters · filed 2021-11-15 | $27.00K 10-Q · filed 2021-11-15 | $30.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $8.00K 10-Q · filed 2021-08-12 | $9.00K 10-Q · filed 2021-08-12 | $12.00K derived: sum of 3 quarters · filed 2021-08-12 | $3.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.00K 10-Q · filed 2021-05-13 | $4.00K derived: sum of 2 quarters · filed 2021-05-13 | -$5.00K derived: sum of 3 quarters · filed 2021-05-13 | $17.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$6.00K derived: sum of 2 quarters · filed 2021-03-29 | $16.00K derived: sum of 3 quarters · filed 2021-03-29 | $7.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | -$9.00K 10-Q · filed 2020-11-16 | $13.00K derived: sum of 2 quarters · filed 2020-11-16 | $4.00K 10-Q · filed 2020-11-16 | $162.00K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $22.00K 10-Q · filed 2020-08-12 | $13.00K 10-Q · filed 2020-08-12 | $171.00K derived: sum of 3 quarters · filed 2020-08-12 | $155.00K derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | -$9.00K 10-Q · filed 2020-05-14 | $149.00K derived: sum of 2 quarters · filed 2020-05-14 | $133.00K derived: sum of 3 quarters · filed 2020-05-14 | |
| 2018-12-31 | $158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $142.00K derived: sum of 2 quarters · filed 2020-03-26 | $151.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | -$16.00K 10-Q · filed 2019-11-18 | -$7.00K 10-Q · filed 2019-11-18 | ||
| 2017-12-31 | -$8.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |